MSD Taiwan
Local branch of a global, research-focused biopharmaceutical company operating in Taiwan for 30+ years. Activities reported in Taiwan include design and conduct of interventional clinical trials with local site management and patient recruitment, R&D across oncology, vaccines and infectious and cardio‑metabolic diseases, regulatory interactions including emergency use authorizations, collaborative translational research with hospitals and academic partners, workforce development for clinical research staff, and local community health and diversity/equity initiatives.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Designing and running interventional clinical trials, site monitoring, participant recruitment and local data collection for multinational studies.
Partnerships with hospitals and universities to develop biomarkers, apply AI analytics to clinical datasets, and advance precision‑medicine research.
Local participation in vaccine and therapeutic R&D programs, including clinical testing and regulatory support for market authorization.
Local community health initiatives (maternal health transport services, patient volunteer activities) and internal employee resource groups that support diversity and inclusion.
Designing and running interventional clinical trials, site monitoring, participant recruitment and local data collection for multinational studies.
Partnerships with hospitals and universities to develop biomarkers, apply AI analytics to clinical datasets, and advance precision‑medicine research.
Local participation in vaccine and therapeutic R&D programs, including clinical testing and regulatory support for market authorization.
Local community health initiatives (maternal health transport services, patient volunteer activities) and internal employee resource groups that support diversity and inclusion.
Expertise Areas
- Clinical trial management
- Vaccine development
- Infectious disease therapeutics
- Immuno‑oncology
Key Technologies
- Immunotherapy (checkpoint inhibitors)
- Recombinant vaccine technologies
- Antiviral small‑molecule development
- Clinical trial data management and monitoring
News & Updates
Local immuno‑oncology clinical programs and related research received national innovation awards; reporting notes >100 clinical trials in Taiwan and collaborations with local universities.
MOU to collaborate on AI clinical platforms, biomarker discovery and precision medicine tools for cancer and infectious diseases.
Description of involvement in COVID‑19 therapeutic development and manufacturing support collaborations during the pandemic, and engagement with government and public health partners.
Public reporting of substantial global R&D investment and a growing number of late‑stage trials and local clinical trial activity.
Local immuno‑oncology clinical programs and related research received national innovation awards; reporting notes >100 clinical trials in Taiwan and collaborations with local universities.
MOU to collaborate on AI clinical platforms, biomarker discovery and precision medicine tools for cancer and infectious diseases.
Description of involvement in COVID‑19 therapeutic development and manufacturing support collaborations during the pandemic, and engagement with government and public health partners.
Public reporting of substantial global R&D investment and a growing number of late‑stage trials and local clinical trial activity.